AprèsFlex® 5-Day Joint Support
Flexibility is Freedom
When we play a round of golf or spend an afternoon on our knees in the garden or just take a nice long walk, we are celebrating our freedom.
AprèsFlex has been giving people back their freedom for almost a decade, by delivering joint comfort and flexibility from 100 mg dose that starts to work in only 5 days.
Around the world, people have turned to AprèsFlex more than a billion times as a drug-free approach to joint comfort. They trust the science. Trust the quality. And trust the experience.
Three Gold Standard Human Clinical Trials
AprèsFlex has been the subject of seven pre-clinical and three human clinical studies. In the newest clinical study, Karlapudi and colleagues examined the efficacy of AprèsFlex in the management of joint comfort and function in a randomized, double-blind, placebo clinical trial. Sixty-seven subjects received either 100 mg/day of AprèsFlex or a matching placebo for thirty days.
- Visual Analog Score (VAS) (Graph A)
- The Lequesne algofunctional index (LFI) (Graph B)
- The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (Graph C/D/E)
- Serum biomarkers (MMP3, TNF, hsCRP, COMP, CPII and C2C)
Measurements were done on Days 0, 5 and 30.
The study showed that AprèsFlex:
-Provided significant reduction (p<0.05) in all the pain scores at five days compared to the placebo.
-Provided significant reduction (p<0.05) in all function scores at five days compared to placebo.
Post-trial, VAS, LFI, WOMAC pain, WOMAC stiffness, WOMAC function, and total WOMAC scores decreased in the AprèsFlex group by 45%, 40.9%, 44.4%, 66.3%, 44.4%, and 48%, respectively.
Beyond joint comfort and function improvements, AprèsFlex was also shown to offer statistically significant impact on biological markers associated with joint health and inflammation metabolism, including TNF-alpha, C-Reactive Protein (CRP), and Interleukin-6 (IL-6). It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), an enzyme that breaks down cartilage, collagen, and connective tissue.
Previous studies with AprèsFlex showed 56% reduction in pain scores at 30 days. A similar study with AprèsFlex showed a 69% reduction in pain scores at 90 days.
In Sprague Dawley rats, acute oral LD50 of AprèsFlex was determined to be > 5000 mg/kg. Acute dermal LD50 was > 2000 mg/kg. No changes in body weight or adverse effects were observed. In a subacute 28-day repeat dose toxicity study, the NOAEL was determined to be > 2500 mg/kg. No abnormal changes related to the study product were demonstrated in hematology, clinical chemistry, or histopathology. No adverse effects were observed.
For more information on AprèsFlex science, see the Resources section below.
A Sustainable and Socially-Responsible Ingredient
When your customers purchase a product featuring AprèsFlex, they become part of a story that is both sustainable and socially responsible. AprèsFlex is based on a proprietary Boswellia serrata gum resin extracts. Over the last 25 years, PLT has worked with our innovation partner – Laila Nutraceuticals – to create an environment that can assure not only the highest quality ingredient with proven efficacy, but an ingredient that you and your customers can be proud of.
PLT Boswellia serrata materials are sourced in India from the states of Andhra Pradesh and Madhya Pradesh. The entire Boswellia serrata supply chain starts with deep, long-term relationships developed with the most trustworthy collectors and aggregators that has been decades in the making. In conjunction with the Indian forestry department, collectors are trained on sustainable gum tapping methodology to maximize yield while maintaining the safety and health of the Boswellia serrata tree populations. Tapping locations on the tree bark as well as the frequency of tapping are carefully controlled to maintain good tree health.
In early 2022, PLT Health Solutions announced the commencement of a third-party sustainability audit program on Boswellia serrata trees in India by renowned botanical research consultancy Botanical Liaisons, LLC. The third-party audit program is based on a broad range of environmental, cultural and economic parameters
At PLT, we understand that proper stewardship of natural resources and social responsibility toward the communities that support our work is both the right thing to do and good business.
PLT Mobility Solutions
At PLT, we are working on the concept of Mobility Solutions – making these solutions available for people of all ages and walks of life. We’re thinking about athletes who want to perform better and recover faster. We’re thinking about people who have physically demanding jobs who don’t want to or can’t take a day off from work. We’re thinking about anyone who has an active lifestyle who wants to embrace it in spite of the rigors. And yes, we’re thinking about the global aging population.
PLT Health Solutions’ leading portfolio of mobility support ingredients – based on more than a decade of ongoing research – has been developed to help you deliver innovative products that can capture the attention and the trust of consumers. All of our ingredients are backed by multiple clinical studies – and offer rapid improvements from a low dose – in just about any delivery system you can imagine.